title: BCG for upper-tract transitional-cell carcinoma: is it safe in patients with renal compromise?
abstract: We report three cases of end-stage renal failure necessitating hemodialysis subsequent to BCG administration for the treatment of upper-urinary tract transitional-cell carcinoma in patients with a solitary kidney, one with normal renal function and two with chronic renal failure prior to BCG instillation. We discuss treatment-related issues with pertinent literature review.
authors.affiliation: Division of Urology, Department of Surgery, Royal Victoria Hospital, McGill University, Montréal, Québec, Canada. surgon@hotmail.com
authors.forename: Saleh
authors.initials: S
authors.lastname: Binsaleh
authors.forename: Kanishka
authors.initials: K
authors.lastname: Sircar
authors.forename: Mostafa
authors.initials: M
authors.lastname: Elhilali
authors.forename: Maurice
authors.initials: M
authors.lastname: Anidjar
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology
chemical_list: D001500:BCG Vaccine